Celgene acquires Triphase’s MRZ

Celgene Corp. has purchased Triphase Accelerator Corp.'s assets regarding its proteasome inhibitor, marizomib (MRZ), which is being developed for the treatment of glioblastoma and relapsed and/or refractory multiple myeloma.
“This acquisition validates the potential of marizomib based on early clinical results. Our vision is to become a leading early stage oncology drug development company, and this first opt-in by Celgene brings us a step closer to achieving that goal,” Triphase Accelerator Corporation Chief Scientific Officer Mohit Trikha said. “Just as importantly, this transaction affords us the opportunity to accelerate our efforts on advancing other assets in our pipeline.”
According to the agreement, Triphase will receive a payment from Celgene up front as well as regulatory, approval and sales milestone payments. The financial terms of the agreement have yet to be released.
“Consistent with our deep commitment and passion for the patients, glioblastoma is an area of significant unmet medical need, and Celgene is committed to helping these patients,” Michael Pehl, president of Hemotology Oncology at Celgene, said. "We are pleased with Triphase Accelerator’s rapid and high quality work to date, and we value the exceptional collaboration we have with them to advance marizomib."